Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MGMT | P16455 | 4/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | ATP4A | P20648 | 1/20 | 0.43 |
| ▸ | ATP4B | P51164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | TPO | P07202 | 1/20 | 0.43 |
| ▸ | EPX | P11678 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30271317 | 1.00 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1MGMTCDK1CCNB1 | |
| SCHEMBL30026947 | 0.89 | MGMT (0.48) | L3MBTL1MGMTCDK1CCNB1CCNA2 | |
| SCHEMBL20595507 | 0.89 | MGMT (0.48) | L3MBTL1MGMTCDK1CCNB1CCNA2 | |
| Hydrochloric Acid SCHEMBL25369331 | 0.87 | MGMT (0.47) | L3MBTL1MGMTCDK1CCNB1CCNA2 | |
| SCHEMBL26329102 | 0.80 | CYP1A2 (0.46) | L3MBTL1ALDH1A1NUDT1LMNATSHR | |
| SCHEMBL26089894 | 0.76 | MCL1 (0.40) | L3MBTL1ALDH1A1MGMTCDK1CCNB1 | |
| SCHEMBL31375611 | 0.76 | MAOB (0.53) | L3MBTL1ALDH1A1NUDT1LMNATSHR | |
| SCHEMBL17459263 | 0.76 | MAOB (0.53) | L3MBTL1ALDH1A1NUDT1LMNATSHR | |
| SCHEMBL4651410 | 0.76 | LMNA (0.47) | L3MBTL1ALDH1A1MGMTCDK1CCNB1 | |
| SCHEMBL6175892 | 0.76 | PIN1 (0.59) | MGMTPIN1MAPTRAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. | 2025-01-30 | — | — | US | disclosed |
| CN-118043041-A | LPAR1 antagonists and uses thereof | 康蒂内乌姆医疗公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2023014908-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-06-24 | — | — | US | disclosed |
| US-7692011-B2 | 8-hydroxy and 8-mercapto quinazolinones | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-04-06 | — | — | US | disclosed |
| EP-1392280-A4 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | WARNER LAMBERT CO (US) | 2005-11-30 | — | — | EP | disclosed |
| US-6875765-B2 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1392280-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | Abbott GmbH & Co. KG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | WARNER-LAMBERT COMPANY | 2003-05-22 | — | — | US | disclosed |
| WO-2002089749-A2 | ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF | ABBOTT GMBH & CO.KG (DE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096826-A1 | Arylsulfonamide ethers, and methods of use thereof | CASP1, IRAK1, STS | L3MBTL1 2397/4885ALDH1A1 1294/4885MGMT 1122/4885 |
| US-20250034110-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | L3MBTL1 980/4885ALDH1A1 1523/4885MGMT 4876/4885 |
| US-20100160346-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | ACHE, PSEN1, PSEN2 | L3MBTL1 2272/4885ALDH1A1 703/4885MGMT 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.